OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

BIOGEN INC. DL -,0005/  US09062X1037  /

gettex
9/6/2024  9:44:14 PM Chg. -0.850 Volume Bid9:59:58 PM Ask9:59:58 PM Market Capitalization Dividend Y. P/E Ratio
180.450EUR -0.47% 28
Turnover: 5,040.400		 180.850Bid Size: 139 181.300Ask Size: 139 26.39 bill.EUR - -
TeleTrader 8/1 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 7/30 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 7/30 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 7/26 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 7/2 Biogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire 6/28 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 6/24 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 6/10 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 6/3 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 5/30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 5/22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 5/21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 5/16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 5/15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 5/2 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 4/25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 4/24 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 4/23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 4/2 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 3/6 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 3/4 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 2/23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 2/13 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 2/12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
TeleTrader 2/12 Earnings preview: Robinhood, Coinbase and more